Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer

British Journal of Cancer

Volumn 71, Issue 5, 1995, Pages 1003-1007

  Fontaninil, G ^a   Vignatil, S ^a   Bigini, D ^a   Mussi, A ^a   Lucchi, M ^a   Angeletti, C A ^a   Basolo, F ^a   Bevilacqua, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bcl 2; NSCLC; Oncogenes; P53; Prognosis

Indexed keywords

CYCLINE; MONOCLONAL ANTIBODY KI 67; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; FEMALE; GENES, P53; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGE; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN P53; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUPPORT, NON-U.S. GOV'T;

EID: 0029035891     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.193     Document Type: Article

References (34)

1. AISEMBERG AC, WILKES BM, AND JACOBSON JO. (1988). The bcl2 gene is rearranged in many diffuse B-cell lymphomas. Blood, 71, 969–972.
2. ALLRED DC, CLARK GM, ELLEDGE R, et al. (1993). Association of p53 protein expression with tumor cell proliferation rate, AND clinical outcome in node-negative breast cancer. J. Natl Cancer Inst., 85, 200–206.
3. CLEARY ML, SMITH SD, AND SKLAR J. (1984). Cloning, AND structural analysis of cDNAs for bcl2 and a hybrid bcl2/immunoglobulin transcript resulting from the t(14; 18) transcription. Science, 226, 1097–1099.
4. COLOMBEL M, SYMMANS F, GIL S, O’TOOLE KM, et al. (1993). Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143, 390–400.
5. CORDELL JL, FALINI B, ERBER WN, et al. (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase, AND monoclonal anti-alkaline phosphatase (APAAP complex). J. Histochem. Cytochem., 32, 219–222.
6. FONTANINI G, BIGINI D, VIGNATI S, et al. (1993a). p53 expression in non small cell lung cancer: clinical, AND biological correlations. Anticancer Res., 13, 737–742.
7. FONTANINI G, PINGITORE R, BIGINI D, VIGNATI S, PEPE S, RUGGIERO A, AND MACCHIARINI P. (1993b). Growth fraction in non small cell lung cancer estimated by proliferating cell nuclear antigen, AND comparison with Ki-67 labelling, AND DNA flow cytometry data. Am. J. Pathol., 141, 1285–1290.
8. FONTANINI G, VIGNATI S, BIGINI D, MERLO GR, RIBECCHINI A, ANGELETTI CA, BASOLO F, PINGITORE R, AND BEVILACQUA G. (1994). Human non small cell lung cancer: p53 accumulation is an early event, AND persists during metastatic progression. J. Pathol., 174, 23–31.
9. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, AND HARRIS CC. P53 mutation in human cancers. Science, 253, 49–53.
10. KORSMEYER SJ. (1992). BCL2 initiates a new category of oncogenes: regulator of cell death. Blood, 80, 876–879.
11. LANE DP (1992). P53, guardian of the genome. Nature, 358, 15–16.
12. LEEK RD, KAKLAMANIS L, PEZZELLA F, GATTER KC, AND HARRIS AL. (1994). Bcl-2 in normal human breast, AND carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors, AND in situ cancer. Br. J. Cancer, 69, 135–139.
13. LEVINE AJ, MOMAND J, AND FINLEY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453–456.
14. LU QL, POULSOM R, WONG L, AND HANBY AM. (1993). Bcl-2 expression in adult, AND embryonic non-haematopoietic tissue. J. Pathol., 169, 431–437.
15. MARTIN HM, FILIPE MI, MORRIS RW, LANE DP, AND SILVESTRE F. P53 expression, AND prognosis in gastric carcinoma. Int. J. Cancer, 50, 859–862.
16. MCDONNEL TI, DEANE N, PLATT FM, et al. (1989). BCL2 immunoglobulin transgenic mice demonstrate extended B cell survival, AND follicular lymphoproliferation. Cell, 57, 79–88.
17. MINNA JD, PASS H, GALSTEIN E, AND IHDE D. (1989). Cancer of the lung. In Cancer, Principles, AND Practice of Oncology, Devita VT, Heilman S, Rosemberg SA. (eds) pp. 591-705. Philadelphia: JB Lippincott.
18. MINNA JD (1993). The molecular biology of lung cancer pathogenesis. Chest, 103, 445S-56S.
19. MOUNTAIN CF. (1987). The new international staging system for lung cancer. Surg. Clin. N. Am., 67, 925–935.
20. PEZZELLA F, JONES M, RALFKIER E, ERSBOL J, GATTER KC, AND MASON DJ. (1992). Evaluation of bcl2 protein expression, AND 14; 18 translocation as prognostic markers in follicular lymphoma. Br. J. Cancer, 65: 87–89.
21. PEZZELLA F, TURLEY H, KUZU I, et al. (1993a). Bcl-2 protein in non small-cell lung carcinoma. N. Engl. J. Med., 329, 690–694.
22. PEZZELLA F, MORRISON H, JONES M, GATTER KC, LANE C, HARRIS AL, AND MASON DY. (1993b). Immunohistochemical detection of p53 and bcl2 proteins in non-Hodgkin’s lymphoma. Histopathology, 22, 39–44.
23. PILOTTI S, COLLINI P, RILKE F, CATTORETTI G, DEL BO R. AND PIEROTTI MA. (1994). Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J. Pathol., 172, 337–342.
24. PIRIS MA, PEZZELLA F, MARTINEZ-MONTERO JC, et al. (1994). p53 and bcl2 expression in high-grade B-cell lymphomas: correlation with survival time. Br. J. Cancer, 69, 337–341.
25. QUINLAN DC, DAVIDSON AS, SUMMERS CL, WARDEN HE, AND DOSHI HM. (1992). Accumulation of p53 correlates with a poor prognosis in human lung cancer. Cancer Res., 52, 4828–4831.
26. SARKIS AS, DALBAGNI G, CORDON-CARDO C, et al. (1993). Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst., 85: 53–59.
27. SILVESTRINI R, BENINI E, DAIDONE MG, et al. (1993). P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst., 85, 965–970.
28. SILVESTRINI R, VENERONI S, DAIDONE MG, et al. (1994). The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl Cancer Inst., 86, 499–504.
29. THOR AD, MOORE DH, EDGERTON SM, et al. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845–855.
30. TSUJIMOTO J, AND CROCE CM. (1986). Analysis of the structure, transcripts, AND protein products of BCL2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. (USA), 83, 5214–5218.
31. TSUJIMOTO J, IKEGAKI N, AND CROCE CM. (1987). Characterization of the protein product of BCL2, the gene involved in human follicular lymphoma. Oncogene, 2, 3–7.
32. VAUX DL, CORY S, AND ADAMS JM. (1988). BCL2 gene promotes haemopoietic cell survival, AND cooperates with C-myc immortalized pre-B cells. Nature, 335, 440–442.
33. VILLEUNDAS R, PIRIS MA, ORRADRE JL, MOLLEJO M, ALGARA P, SANCHEZ L, MARTINEZ JC, AND MARTINEZ P. (1992). p53 protein expression in lymphomas, AND reactive lymphoid tissue. J. Pathol., 166, 235–241.
34. WORLD HEALTH ORGANIZATION. (1982). The world health organization histological typing of lung cancer. Am. J. Clin Pathol., 77, 123–136.